Compare Freshworks Inc (FRSH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Novavax Inc — how do they compare? Freshworks Inc trades at $13.92 (market cap $3.56B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Freshworks Inc is the larger of the two by market cap, and Freshworks Inc is more actively traded (9,066,454 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Novavax Inc for 59 Days on average.
| FRSH | NVAX | |
|---|---|---|
Market Cap | $3.56B | $1.82B |
Volume | 9,066,454 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $13.92 | $12.75 |
52-Week Low | $6.88 | $6.22 |
Typical Hold Time | 39 Days | 59 Days |
Enterprise Value | $2.93B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.64, up 0.29% with strong technical momentum showing bullish moving average signals. The company achieved its first GAAP profitability in Q2 2026 with revenue growth of 16% year-over-year, beating earnings expectations. Recent developments include FedRAMP certification progress and leadership in Gartner's ITSM Magic Quadrant, positioning the company for enterprise growth.
FRSH presents a compelling investment case with attractive valuation metrics (P/E 21.63, P/S 4.28) and strong profitability margins (84.96% gross margin, 20.49% net margin). However, elevated EV/EBITDA (43.89) and competitive SaaS market pressures require monitoring. Analyst consensus is evenly split between Buy and Hold with $14.60 price target suggesting modest upside potential from current levels.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
